AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 231 min read$IART

Integra LifeSciences 3Q 2026: Revenue $411.18M, Net income $14.85M, EPS $0.19— 10-Q Summary

Integra LifeSciences reported Q3 2026 revenue of $411.18M, up 2.3% YoY, and net income of $14.85M, reversing a prior-year loss. EPS was $0.19, compared to a loss of $0.07. Specialty Surgery revenue grew 4%, while Tissue Reconstruction declined 2%. Flooding in Cincinnati reduced revenue by $7M. The company expects full manufacturing capacity restoration by Q2 2027.

Original reporting
tradingview.com
Published Oct 23, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Integra LifeSciences 3Q 2026: Revenue $411.18M, Net income $14.85M, EPS $0.19— 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$IARTBullishMed
01

Why it matters

Earnings beat and a shift to profitability provide a fresh catalyst for the stock, likely prompting buying interest.

02

Market read

First disclosure of quarterly results for a small‑cap medical device firm, offering a new trading signal.

03

What to watch

Potential lingering effects of the Cincinnati flood on future capacity and the ramp‑up timeline for Braintree.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

The article summarizes Integra LifeSciences' Q3 2026 10‑Q filing, highlighting revenue, profit, and operational updates.

Company-level read

Ticker impact

$IARTBullishHigh confidence
Context

Integra LifeSciences reported Q3 2026 revenue of $411.18M and EPS of $0.19, a turnaround from a loss a year ago.

Expected impact

likely modest upside as the market prices in the earnings beat and restored profitability

Evidence & confidence

First report of quarterly results shows revenue up 2% YoY and a swing to profit, which typically supports a short‑term price rise.

Market effects

Sector

Positive earnings may lift the broader medical device and specialty surgery sector.

Regional

Limited to U.S. markets where the stock trades.

Global

Low, as the company is a small‑cap specialist.

Counterpoint

What could challenge this read

If the revenue growth is modest and the flood impact recurs, the rally could be short‑lived.

Key entities

  • company
    Integra LifeSciences Holdings Corp.

    Medical device manufacturer reporting Q3 2026 results.

Read at source← All news

StoryIntegra LifeSciences reports Q3 results, cites flood impact and cuts Q4 revenue outlook

Also covered by

6 outlets

Related articles

OCT 22
$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.

finance.yahoo.com2 min
OCT 21
$IARTMed

Integra LifeSciences (IART) Reports Q3 Revenue In Line with Guid

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

gurufocus.com3 min